Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Colorectal Neoplasms 13Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3NSCLC 2Endometrial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Burkitt Lymphoma 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Advanced Colorectal Cancer 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × HMPL-013 × Clear all
NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

AskGene Pharma, Inc.

Phase 1/2 Recruiting
594 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

BeiGene

Phase 2 Completed
84 enrolled 17 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡